An In silico Chimeric Vaccine Targeting Breast Cancer Containing Inherent Adjuvant

Area of Science:

• Oncology
• Immunology
• Biotechnology

Background:

• Breast cancer remains a leading cause of death in women, necessitating novel therapeutic strategies.
• The over expression of ROR1 on breast cancer cells, in the absence of HER2/neu and hormone receptors, makes it a viable target for vaccine development.
• Current therapeutic options for breast cancer are limited, particularly for drug-resistant forms.

Purpose of the Study:

• To investigate the potential of a chimeric vaccine construct comprising the extracellular domain of ROR1 and staphylococcal enterotoxin B (SEB) for treating drug-resistant breast cancer.
• To evaluate the antitumor immune properties, stability, physicochemical characteristics, and allergenicity of the designed ROR1-SEB fusion protein using bioinformatics analysis.

Main Methods:

• Bioinformatics analysis was employed to assess the antitumor immune properties of the ROR1-SEB chimeric construct.
• In silico methods were used to investigate the stability, physicochemical properties, and potential allergenicity of the designed fusion protein.

Main Results:

• The chimeric ROR1-SEB construct demonstrated potential as a stimulant for both T-cell and B-cell mediated immune responses.
• Bioinformatics analysis indicated acceptable accessibility and solubility for the designed fusion protein.
• The study found no evidence of allergenicity associated with the ROR1-SEB fusion protein.

Conclusions:

• The ROR1-SEB fusion protein holds promise as a potent vaccine candidate for breast cancer.
• This chimeric approach offers a potential new avenue for developing effective treatments against drug-resistant breast cancer.
• Further research into this ROR1-based vaccine strategy is warranted.